Prurigo nodularis
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
References
Prurigo nodularis hija kundizzjoni tal-ġilda fit-tul ikkaratterizzata minn ħotob u noduli sodi multipli, ġeneralment misjuba fuq il-partijiet ta 'barra tad-dirgħajn u r-riġlejn. Dawn il-ħotob jistgħu jvarjaw fil-kulur minn laħam-toned għal roża u huma intensament ħakk. Jistgħu jaffettwaw lin-nies ta 'kull età u ħafna drabi huma marbuta ma' kundizzjonijiet oħra tal-ġilda li jikkawżaw ħakk kroniku, bħal dermatite atopika. Għażliet ta 'trattament jinkludu mediċini qawwija kontra l-ħakk, mediċini li jaffettwaw is-sistema immuni, u mediċini li jimmiraw is-sistema nervuża. Il-ġestjoni tal-prurigo nodularis normalment tinvolvi terapija fit-tul.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
It-trattament normalment jinvolvi l-użu ta 'kremi jew injezzjonijiet ta' sterojdi fuq iż-żona affettwata. F'każijiet aktar severi jew iebsa, trattamenti bħal terapija ħafifa jew mediċini li jrażżnu s-sistema immuni jistgħu jkunu meħtieġa. Thalidomide u lenalidomide huma għażliet għal każijiet severi, iżda jista 'jkollhom effetti sekondarji serji. Trattamenti aktar ġodda (opioid receptor antagonists, neurokinin-1 receptor antagonists) juru wegħda fit-trattament ta 'prurigo nodularis b'inqas effetti sekondarji meta mqabbla ma' thalidomide jew lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo hija kundizzjoni tal-ġilda kkaratterizzata minn ħakk fit-tul (li jdum aktar minn 6 ġimgħat) , leżjonijiet tal-ġilda relatati mal-grif, u storja ta 'grif frekwenti. Tinvolvi newroinfjammazzjoni u fibrożi fil-ġilda.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis hija problema tal-ġilda fit-tul immarkata minn noduli li ħakk. Ma nafux eżattament x'jikkawżaha, iżda jidher li l-kwistjonijiet immuni u tan-nervituri għandhom rwol fiċ-ċiklu tal-ħakk-grif. Bħalissa, m'hemm l-ebda trattament approvat mill-FDA tal-Istati Uniti speċifikament għal prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Trattament - Drogi OTC
Il-ħasil taż-żona tal-leżjoni bis-sapun ma jgħin xejn u jista 'jagħmilha għall-agħar. L-ingwenti sterojdi OTC jistgħu jgħinu biex itaffu s-sintomi, iżda ġeneralment jeħtieġ li jiġu applikati għal diversi ġimgħat biex itejbu. Li tkompli tieħu anti-istaminiċi tgħin ukoll ittaffi l-ħakk.
#OTC steroid ointment
#OTC antihistamine
○ Trattament
#Intralesional triamcinolone injection